Anal cancer: current and future methodology

Cancer Invest. 2006 Aug-Sep;24(5):535-44. doi: 10.1080/07357900600815208.

Abstract

Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat. For although it is one of the few malignancies that may be cured with chemoradiation alone, the use of combined modality therapy may result in significant treatment-related morbidity. Novel approaches currently are underway in this select patient population and will be addressed for the purposes of this manuscript.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Adenocarcinoma / radiotherapy
  • Antineoplastic Agents / therapeutic use*
  • Anus Neoplasms* / drug therapy
  • Anus Neoplasms* / pathology
  • Anus Neoplasms* / radiotherapy
  • Anus Neoplasms* / virology
  • Carcinoma in Situ / drug therapy
  • Carcinoma in Situ / pathology
  • Carcinoma in Situ / radiotherapy
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / radiotherapy
  • Cisplatin / therapeutic use
  • Clinical Trials as Topic
  • Fluorouracil / therapeutic use
  • HIV Infections / complications
  • Humans
  • Mitomycin / therapeutic use
  • Neoadjuvant Therapy
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Neoplasm, Residual
  • Papillomavirus Infections / complications

Substances

  • Antineoplastic Agents
  • Mitomycin
  • Cisplatin
  • Fluorouracil